In:
International Journal of Cancer, Wiley, Vol. 140, No. 4 ( 2017-02-15), p. 922-929
Kurzfassung:
What's new? Monoclonal antibodies targeting the epidermal growth factor receptor (EGFR) are an important therapeutic option for patients with RAS wild‐type metastatic colorectal cancer. However, the efficacy of anti‐EGFR therapy may be undermined by the presence of mutations in other EGFR pathway genes. According to this study, in order to better predict anti‐EGFR therapeutic response, the addition of EGFR gene copy number (GCN) analysis to the biomarker panel used today seems to be a promising approach. EGFR GCN of ≥ 4.0 predicted positive response and favourable survival in anti‐EGFR‐treated RAS / BRAF / PIK3CA wild‐type patients. No survival benefits were detected, however, when EGFR GCN was below 4.0.
Materialart:
Online-Ressource
ISSN:
0020-7136
,
1097-0215
Sprache:
Englisch
Verlag:
Wiley
Publikationsdatum:
2017
ZDB Id:
218257-9
ZDB Id:
1474822-8